Group 1 - Agilysys reported quarterly earnings of $0.54 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and showing an increase from $0.32 per share a year ago, resulting in an earnings surprise of 107.69% [1] - The company achieved revenues of $74.27 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.20%, and up from $62.22 million year-over-year [2] - Agilysys has outperformed consensus EPS estimates in all four of the last quarters [2] Group 2 - The stock has underperformed the market, losing approximately 34.7% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $73.98 million, and for the current fiscal year, it is $1.63 on revenues of $317.63 million [7] - The Computer - Integrated Systems industry, to which Agilysys belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Gilat Satellite (GILT) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -57.14%. A quarter ago, it was expected that this satellite broadband communications company would post earnings of $0.14 per share when it actually produced earnings of $0.15, delivering a surprise of 7.14%.Over t ...

Core Viewpoint - Karyopharm Therapeutics (KPTI) shows significant upside potential with a mean price target of $33.07, indicating a 521.6% increase from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $8 to $67.47, with a standard deviation of $23.37, suggesting a high variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 50.4%, while the highest suggests an upside of 1168.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising KPTI's earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 4.9% rise in the Zacks Consensus Estimate for the current year [12] - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - RBC Bearings reported quarterly earnings of $2.83 per share, exceeding the Zacks Consensus Estimate of $2.68 per share, and showing an increase from $2.47 per share a year ago, representing an earnings surprise of 5.60% [1][2] Financial Performance - The company posted revenues of $437.7 million for the quarter ended March 2025, which was 0.71% below the Zacks Consensus Estimate, compared to $413.68 million in the same quarter last year [2] - Over the last four quarters, RBC Bearings has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Stock Performance - RBC Bearings shares have increased approximately 22.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.6% [3] Future Outlook - The company's earnings outlook will be crucial for determining the stock's immediate price movement, with current consensus EPS estimates at $2.65 for the coming quarter and $11.10 for the current fiscal year [4][7] - The estimate revisions trend for RBC Bearings is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Manufacturing - General Industrial industry, to which RBC Bearings belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Group 1: Company Performance - United Natural Foods (UNFI) shares increased by 7.6% to close at $30.57, with notable trading volume compared to typical sessions, and a total gain of 17.3% over the past four weeks [1][2] - The stock's rise is driven by optimism regarding its wholesale segment, new business from existing and newly acquired customers, and the impact of inflation, alongside a focus on lean management and operational efficiency [2] - The company is expected to report quarterly earnings of $0.23 per share, reflecting a year-over-year increase of 130%, with revenues projected at $7.82 billion, up 4.2% from the previous year [3] Group 2: Earnings Estimates and Market Position - The consensus EPS estimate for UNFI has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - UNFI currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, Campbell's (CPB), has a Zacks Rank of 4 (Sell) and reported a 1.9% increase in its last trading session [4][5] - Campbell's EPS estimate for the upcoming report is $0.65, which is a decrease of 13.3% from the previous year [5]

Pedevco Corp. (PED) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.13, delivering a surprise of 1,200%.Over the last four quarters, the company has surpassed conse ...

Flexible Solutions International Inc. (FSI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.05. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -140%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.05, delivering no surprise.Over the last four quarters, the company has ...

Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.45 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $1.63 per share a year ago [1] - The company posted revenues of $3.02 million for the quarter, missing the Zacks Consensus Estimate by 18.49%, and down from $3.42 million in the same quarter last year [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates [2] Stock Performance - Vivos Therapeutics shares have declined approximately 29.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The current Zacks Rank for Vivos Therapeutics is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $4.2 million, and for the current fiscal year, it is -$1.54 on revenues of $16.6 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]

Cava Group (CAVA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.14%. A quarter ago, it was expected that this Mediterranean restaurant chain would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.Over the last four qua ...

LightPath Technologies, Inc. (LPTH) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.07, delivering a surprise of -75%.Over the last four quarters, the company ha ...